ЧАСТОТА АЛЛЕЛЕЙ И ГЕНОТИПОВ ПО АЛЛЕЛЬНЫМ ВАРИАНТАМ CYP2С9*2 И CYP2С9*3 СРЕДИ БОЛЬНЫХ С БОЛЕВЫМ СИНДРОМОМ, ПРИНИМАВШИХ НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ СРЕДСТВА

Abstract

Abstract. Introduction. The most clinically significant polymorphic markers of the CYP2C9 gene are the amino acid substitutions of CYP2C9*2. One of the types of human cytochrome P450 – cytochrome CYP2C19 plays an important role in the metabolism of certain drugs, including proton pump inhibitors. The genetic polymorphism of СУР2С19 has pronounced interindividual differences. The significance of genetic polymorphism is determined when the occurrence of variant alleles is more than 1% in the population. Aim. The aim of the study was to improve the principles of pharmacotherapy of nonsteroidal anti-inflammatory drugs depending on the frequency of alleles and genotypes according to allelic variants of CYP2С9*2 and CYP2С9*3 in patients with pain syndrome, who took nonsteroidal anti-inflammatory drugs. Material and methods. The study included 69 patients with pain syndrome. The study of the association between the carrier of genotypes according to the CYP2С9*2 and CYP2С9*3 alleles and the development of gastropathies with the use of anti-inflammatory drugs was carried out by conducting a prospective case-control study. Molecular genetic studies were carried out on the basis of the Laboratory of Medical Genetics, the Research Institute of Hematology and Blood Transfusion of the Ministry of Health of the Republic of Uzbekistan. Results and discussion. Our data suggest that the carriage of allelic variants of CYP2C9*2 and CYP2C9*3 should be considered as a risk factor for the development of gastropathies when using anti-inflammatory drugs. It can be assumed that in order to reduce the risk of adverse drug reactions when using anti-inflammatory drugs in this category of patients, their joint administration with proton pump inhibitors is necessary. Conclusion. Significantly significant differences in the frequencies of CYP2C9 and CYP2C19 alleles between groups of patients with and without complications from the gastrointestinal tract while taking anti-inflammatory drugs and proton pump inhibitors. Therefore, it is necessary to further study the frequencies of alleles and genotypes according to the allelic variants of CYP2С9*2 and CYP2С9*3 among patients with pain syndrome who took anti-inflammatory drugs.